The administration of the STAT pathway inhibitors tocilizumab and itacitinib can play a role in reducing the expression levels of cytokines such as IL-6 and IFNγ in patients or animal models suffering with CRS after anti-CD19 CAR-T cell therapy [107,108]. The gene discussed is IL6; the disease is congenital rubella syndrome.